×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
NASDAQ:NBSE

NeuBase Therapeutics Stock Forecast, Price & News

$0.85
-0.04 (-4.49%)
(As of 06/24/2022 04:00 PM ET)
Add
Compare
Today's Range
$0.79
$0.98
50-Day Range
$0.82
$1.50
52-Week Range
$0.79
$5.45
Volume
63,513 shs
Average Volume
50,415 shs
Market Capitalization
$27.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50
30 days | 90 days | 365 days | Advanced Chart

Receive NBSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuBase Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NBSE Stock Forecast (MarketRank)

Overall MarketRank

2.30 out of 5 stars

Medical Sector

277th out of 1,411 stocks

Pharmaceutical Preparations Industry

112th out of 672 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
NeuBase Therapeutics logo

About NeuBase Therapeutics (NASDAQ:NBSE)

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

NBSE Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NBSE
Fax
N/A
Employees
33
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
6/26/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
9/30/2022

Price Target and Rating

Average Stock Price Forecast
$9.50
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+1,017.6%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
1 Analysts

Profitability

Net Income
$-25.41 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.65 per share

Miscellaneous

Free Float
27,356,000
Market Cap
$27.42 million
Optionable
Not Optionable
Beta
0.79














NeuBase Therapeutics Frequently Asked Questions

Should I buy or sell NeuBase Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeuBase Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NeuBase Therapeutics stock.
View analyst ratings for NeuBase Therapeutics
or view top-rated stocks.

What is NeuBase Therapeutics' stock price forecast for 2022?

1 brokerages have issued twelve-month price objectives for NeuBase Therapeutics' shares. Their NBSE stock forecasts range from $9.00 to $10.00. On average, they predict NeuBase Therapeutics' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 1,017.6% from the stock's current price.
View analysts' price targets for NeuBase Therapeutics
or view top-rated stocks among Wall Street analysts.

How has NeuBase Therapeutics' stock performed in 2022?

NeuBase Therapeutics' stock was trading at $2.81 at the start of the year. Since then, NBSE stock has decreased by 69.8% and is now trading at $0.85.
View the best growth stocks for 2022 here
.

When is NeuBase Therapeutics' next earnings date?

NeuBase Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for NeuBase Therapeutics
.

How were NeuBase Therapeutics' earnings last quarter?

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) posted its quarterly earnings results on Thursday, May, 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.04.
View NeuBase Therapeutics' earnings history
.

Who are NeuBase Therapeutics' key executives?

NeuBase Therapeutics' management team includes the following people:
  • Dr. Dietrich A. Stephan Ph.D., Founder, Pres, CEO & Chairman (Age 52, Pay $713.83k) (LinkedIn Profile)
  • Dr. William Roland Mann MBA, Ph.D., Chief Operating Officer (Age 62, Pay $470.4k)
  • Mr. Todd P. Branning, Chief Financial Officer (Age 51)
  • Dr. Anthony Rossomando Ph.D., Chief Technology Officer
  • Dr. Curt Bradshaw Ph.D., Chief Scientific Officer (Age 57)
  • Mr. Alan Scrivner J.D., VP of IP & Legal
  • Ms. Shannon McCarthy, Chief People Officer
  • Dr. Sandra Rojas-Caro M.D., Head of R&D and Chief Medical Officer (Age 52)
  • Dr. Robert J. Zamboni Ph.D., Chief of Preclinical Devel. & Member of Scientific Advisory Board

What other stocks do shareholders of NeuBase Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuBase Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Flexion Therapeutics (FLXN), Pfizer (PFE), VBI Vaccines (VBIV), AbbVie (ABBV) and Aravive (ARAV).

What is NeuBase Therapeutics' stock symbol?

NeuBase Therapeutics trades on the NASDAQ under the ticker symbol "NBSE."

Who are NeuBase Therapeutics' major shareholders?

NeuBase Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.23%), AIGH Capital Management LLC (3.14%), Decheng Capital Management III Cayman LLC (3.05%), CM Management LLC (0.99%), Worth Venture Partners LLC (0.80%) and Renaissance Technologies LLC (0.66%). Company insiders that own NeuBase Therapeutics stock include Dietrich A Stephan, Eric I Richman, Samuel Backenroth, Todd P Branning and William Roland Mann.
View institutional ownership trends for NeuBase Therapeutics
.

Which institutional investors are selling NeuBase Therapeutics stock?

NBSE stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc..
View insider buying and selling activity for NeuBase Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying NeuBase Therapeutics stock?

NBSE stock was purchased by a variety of institutional investors in the last quarter, including Decheng Capital Management III Cayman LLC, CM Management LLC, Renaissance Technologies LLC, Waldron Private Wealth LLC, Royal Bank of Canada, Perkins Capital Management Inc., Worth Venture Partners LLC, and AIGH Capital Management LLC. Company insiders that have bought NeuBase Therapeutics stock in the last two years include Dietrich A Stephan, Eric I Richman, Todd P Branning, and William Roland Mann.
View insider buying and selling activity for NeuBase Therapeutics
or or view top insider-buying stocks.

How do I buy shares of NeuBase Therapeutics?

Shares of NBSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeuBase Therapeutics' stock price today?

One share of NBSE stock can currently be purchased for approximately $0.85.

How much money does NeuBase Therapeutics make?

NeuBase Therapeutics (NASDAQ:NBSE) has a market capitalization of $27.42 million. The company earns $-25.41 million in net income (profit) each year or ($1.04) on an earnings per share basis.

How many employees does NeuBase Therapeutics have?

NeuBase Therapeutics employs 33 workers across the globe.

How can I contact NeuBase Therapeutics?

NeuBase Therapeutics' mailing address is 700 TECHNOLOGY DRIVE, PITTSBURGH PA, 15219. The official website for NeuBase Therapeutics is www.neubasetherapeutics.com. The company can be reached via phone at (164) 645-1790 or via email at [email protected].

This page (NASDAQ:NBSE) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.